MG
APRE icon

Michael Gelband’s Aprea Therapeutics APRE Stock Holding History

Michael Gelband’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-866
Closed -$50K – 2169
2021
Q4 		$50K Buy
+866
New +$76.5K ﹤0.01% 2031
2021
Q2 		– Sell
-616
Closed -$63K – 2308
2021
Q1 		$63K Buy
+616
New +$71.9K ﹤0.01% 2014
2020
Q2 		– Sell
-301
Closed -$209K – 1752
2020
Q1 		$209K Buy
+301
New +$221K 0.01% 774

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Michael Gelband's APRE Position: Q1 2022 in Review

Michael Gelband sold out of Aprea Therapeutics (APRE) in Q1 2022, closing a stake of 866 shares — an estimated $50K sold.

Michael Gelband first reported a position in APRE in Q1 2020 and held it in 3 quarters. The position peaked at $209K in Q1 2020. 40 funds tracked by Wall St. Rank hold APRE as of Q1 2022.

  • Michael Gelband reported no remaining Aprea Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Michael Gelband sold 866 Aprea Therapeutics shares in Q1 2022, an estimated $50K.
  • Michael Gelband first reported a position in Aprea Therapeutics in Q1 2020 and held it in 3 quarters.
  • Michael Gelband's Aprea Therapeutics position peaked at $209K in Q1 2020.
  • 40 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.